Item 7.01. Regulation FD Disclosure
On
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Item 8.01. Other Events
On
Forward-Looking Statements; Risks and Uncertainties
This Current Report on Form 8-K contains forward-looking statements that are
made pursuant to the safe harbor provisions within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements include, but
are not limited to, statements related to the submission of Cotempla to the FDA.
Forward-looking statements are based on management's current expectations and
are subject to risks and uncertainties, many of which are beyond the Company's
control, that may cause actual results or events to differ materially from those
projected. These risks and uncertainties include risks described in the section
entitled "Risk Factors" and elsewhere in the Company's Annual Report on Form
10-K and in our other filings with the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Description 99.1 Press release datedApril 27, 2023 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
© Edgar Online, source